Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Recruiting now

Conditions studied: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

In brief

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Key facts

Study ID
NCT05430971
Run by
Immune Oncology Research Institute
People needed
200
Starts
2022-07-01
Expected to finish
2032-07-01
Last updated by the study team
2026-06-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.